nPhase launched an AI platform aimed at accelerating the generation of regulatory submissions for clinical trials. The company says the tool can convert raw study data into submission-ready materials 75% to 80% faster than traditional workflows. The product targets a high-friction segment of trial operations—turning distributed, heterogeneous clinical data into the documentation regulators require—by automating parts of the preparation process that usually rely on manual review. If the time savings hold in real submission pipelines, the platform could change contracting and internal planning for biotechs that rely on CRO data packages and tight regulatory timelines.